Statement reviewed and approved by AAEM Board of Directors. (11/10/2021)
Summary Recommendation:
- Febrile Neutropenia risk stratifications tools, such as the Multinational Association of Supportive Care in
Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores, are supported by the
existing literature and may be included as part of the decision-making process when considering adult
patient disposition. There is no widely accepted risk stratification tool for use in the pediatric population. - Further research is needed before biomarkers can be included in febrile neutropenia risk stratification
decisions.